Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1663812

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1663812

Diabetic Retinopathy Market Size, Share, and Growth Analysis, By Type, By Treatment, By Diagnosis, By Route of Administration, By End-Users, By Distribution Channel, By Region - Industry Forecast 2025-2032

PUBLISHED:
PAGES: 219 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Diabetic Retinopathy Market size was valued at USD 9.5 billion in 2023 and is poised to grow from USD 10.16 billion in 2024 to USD 17.32 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The diabetes market is poised for significant growth, driven by the escalating prevalence of diabetes, an aging population, and the increasing incidence of diabetes-related blindness. Heightened awareness about diabetes and the introduction of innovative products are further accelerating this trend. The condition arises from the pancreas's inability to produce insulin, leading to elevated blood sugar levels and potential damage to retinal blood capillaries, resulting in diabetic retinopathy. Early identification and intervention, continuous self-monitoring using advanced tools, and lifestyle changes are crucial for mitigating these risks. Recent initiatives, such as Check Eye's AI-powered platform for diabetic retinopathy screening, underscore efforts to enhance early detection. Additionally, rising healthcare spending and the projected tripling of the elderly population by 2050 will be vital in shaping market dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetic Retinopathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetic Retinopathy Market Segments Analysis

Global Diabetic Retinopathy Market is segmented by Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. Based on Treatment, the market is segmented into Medication, Through Device, Surgery and Others. Based on Diagnosis, the market is segmented into Fluorescein Angiography, Optical Coherence Tomography and Others. Based on Route of Administration, the market is segmented into Oral, Intravitreal Injections, Intravitreal Implants, Topical Eye Drops, Laser Surgery, Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetic Retinopathy Market

The diabetic retinopathy market is primarily driven by the rising global incidence of diabetes, which significantly heightens the prevalence of this common complication among diabetic patients. As more individuals are diagnosed with diabetes, the need for effective diagnostic tools and treatment solutions for diabetic retinopathy intensifies. This escalating diabetic population not only underscores the necessity for innovative therapies but also creates an expanding market for specialists and healthcare providers focused on managing and addressing the visual impairments associated with this condition. Consequently, the urgent demand for effective interventions stands as a vital propellant for the growth of the diabetic retinopathy market.

Restraints in the Diabetic Retinopathy Market

The diabetic retinopathy market faces several challenges that hinder its growth. A significant issue is the insufficient awareness among diabetic patients regarding the condition and the critical need for routine eye check-ups. Many individuals remain unaware of the risks associated with diabetic retinopathy, which can lead to severe vision impairment if not addressed promptly. Additionally, access to eye care services is often limited in remote or underserved regions, creating barriers to early detection and timely treatment. These factors collectively restrict the market's potential, underscoring the need for increased education and improved healthcare accessibility to mitigate these restraints.

Market Trends of the Diabetic Retinopathy Market

The diabetic retinopathy market is witnessing a notable trend towards early detection and intervention, driven by an increasing acknowledgment of the condition's progressive nature. Healthcare providers are investing in regular screening programs and community awareness campaigns to educate patients about the importance of timely diagnosis. Concurrently, advancements in imaging technologies, such as OCT and fundus photography, are enhancing the precision of early diagnosis. This proactive approach not only aims to reduce the incidence of severe vision loss but also to optimize treatment outcomes, thereby shaping the market dynamics and stimulating growth as both healthcare systems and patients prioritize preventive strategies.

Product Code: SQMIG35A2516

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Regulatory Analysis
  • Patent Analysis
  • Technology Analysis

Global Diabetic Retinopathy Market Size by Type & CAGR (2025-2032)

  • Market Overview
  • Non-Proliferative Diabetic Retinopathy
  • Proliferative Diabetic Retinopathy

Global Diabetic Retinopathy Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Medication
  • Through Device
  • Surgery
  • Others

Global Diabetic Retinopathy Market Size by Diagnosis & CAGR (2025-2032)

  • Market Overview
  • Fluorescein Angiography
  • Optical Coherence Tomography
  • Others

Global Diabetic Retinopathy Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Oral
  • Intravitreal Injections
  • Intravitreal Implants
  • Topical Eye Drops
  • Laser Surgery
  • Others

Global Diabetic Retinopathy Market Size by End-Users & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Global Diabetic Retinopathy Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Global Diabetic Retinopathy Market Size & CAGR (2025-2032)

  • North America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
    • US
    • Canada
  • Europe (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oxurion NV (Belgium)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sirnaomics (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alimera Sciences (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ampio Pharmaceuticals Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kowa Company Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genentech, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneron Pharmaceuticals Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Holding AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan PLC (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Carl Zeiss Meditec AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Topcon Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Heidelberg Engineering GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Optos PLC (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Canon Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nidek Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bausch + Lomb Incorporated (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!